Embecta Corp.

Embecta Corp. (NASDAQ: EMB) is a leading global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The company operates independently following its spinoff from Becton, Dickinson and Company in April 2022. Embecta's website is located at www.embecta.com.

The company's core business centers on diabetes management devices, with a broad portfolio of marketed products including conventional and safety pen needles, insulin syringes, and safety injection devices. Pen needles represent the largest product category, accounting for approximately 73 percent of total net revenues. These sterile, single-use medical devices are designed for use with pen injectors that administer insulin and other diabetes medications. Embecta's products are used by more than 30 million people across over 100 countries.

Embecta operates a global manufacturing and distribution network with three manufacturing sites located in Ireland, the United States, and China. The company distributes products through multiple channels including retail, hospitals, pharmacies, and other institutional channels. As of September 30, 2025, Embecta employed approximately 1,850 regular employees globally, with roughly 700 based in the United States.

The company maintains a substantial intellectual property portfolio protecting its core injection business, holding approximately 655 patents in the United States and various foreign countries, along with approximately 45 pending patent applications worldwide. Embecta also holds approximately 455 trademark registrations and 160 pending trademark applications globally.

A significant portion of Embecta's revenue is derived from sales to major distributors, with the three largest distributors representing approximately 42 percent of worldwide gross sales. The company faces competition from established medical device manufacturers and pharmaceutical companies developing alternative diabetes treatment technologies. Embecta's business model relies on continuous innovation, strong relationships with healthcare providers and payers, and efficient global supply chain management. The company sources raw materials and components from third parties, including a critical cannula supply agreement with its former parent company BD, which retains ownership of cannula production activities and related intellectual property.